Sphingomyelin synthase 1 activity is regulated by the BCR-ABL oncogene[S]
暂无分享,去创建一个
K. Bhalla | Daohong Zhou | Xiao-fei Yang | C. Luberto | T. Burns | P. Signorelli | Young Choi | Yong Wang | M. Subathra | M. Villani
[1] M. Dimanche-Boitrel,et al. Targeting the ceramide system in cancer. , 2013, Cancer letters.
[2] L. Obeid,et al. Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. , 2012, Anti-cancer agents in medicinal chemistry.
[3] S. Summers,et al. Ceramides as modulators of cellular and whole-body metabolism. , 2011, The Journal of clinical investigation.
[4] K. Schulze-Osthoff,et al. Caspase-mediated inhibition of sphingomyelin synthesis is involved in FasL-triggered cell death , 2010, Cell Death and Differentiation.
[5] J. Melo,et al. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway , 2010, Oncogene.
[6] M. Tani,et al. Sphingomyelin synthase 2 is palmitoylated at the COOH-terminal tail, which is involved in its localization in plasma membranes. , 2009, Biochemical and biophysical research communications.
[7] Jorge Cortes,et al. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. , 2009, Blood.
[8] P. Lu,et al. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase 3 in colon cancer cells , 2008, Oncogene.
[9] M. Konopleva,et al. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK , 2008, Cell cycle.
[10] Renxiao Wang,et al. The domain responsible for sphingomyelin synthase (SMS) activity. , 2008, Biochimica et biophysica acta.
[11] M. Del Poeta,et al. Sphingomyelin synthases regulate production of diacylglycerol at the Golgi. , 2008, The Biochemical journal.
[12] A. Tarca,et al. Suppression of sphingomyelin synthase 1 by small interference RNA is associated with enhanced ceramide production and apoptosis after photodamage. , 2008, Experimental cell research.
[13] J. Melo,et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells , 2008, Leukemia.
[14] F. Maxfield,et al. SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis Published, JLR Papers in Press, November 2, 2007. , 2008, Journal of Lipid Research.
[15] J. Sessions. Chronic myeloid leukemia in 2007. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[16] J. Apperley. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. , 2007, The Lancet. Oncology.
[17] D. Peake,et al. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization. , 2007, Biochimica et biophysica acta.
[18] M. Tainsky,et al. Sphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamage. , 2007, Biochemical and biophysical research communications.
[19] Martin Hermansson,et al. Both Sphingomyelin Synthases SMS1 and SMS2 Are Required for Sphingomyelin Homeostasis and Growth in Human HeLa Cells* , 2007, Journal of Biological Chemistry.
[20] L. Obeid,et al. Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells* , 2007, Journal of Biological Chemistry.
[21] M. Kazanietz,et al. Protein kinase C and other diacylglycerol effectors in cancer , 2007, Nature Reviews Cancer.
[22] Y. Hannun,et al. Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas , 2007, Molecular Cancer Therapeutics.
[23] J. Dutcher,et al. Blastic phase of chronic myelogenous leukemia , 2005, Current treatment options in oncology.
[24] S. Marley,et al. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. , 2005, Clinical science.
[25] R. Ren,et al. Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia , 2005, Nature Reviews Cancer.
[26] Jacek Bielawski,et al. Role for Mammalian Neutral Sphingomyelinase 2 in Confluence-induced Growth Arrest of MCF7 Cells* , 2004, Journal of Biological Chemistry.
[27] B. Druker,et al. Lessons learned from the development of imatinib. , 2004, Leukemia research.
[28] Shohei Yamaoka,et al. Expression Cloning of a Human cDNA Restoring Sphingomyelin Synthesis and Cell Growth in Sphingomyelin Synthase-defective Lymphoid Cells* , 2004, Journal of Biological Chemistry.
[29] O. Witte,et al. The BCR-ABL story: bench to bedside and back. , 2004, Annual review of immunology.
[30] H. Umehara,et al. Increase of Nuclear Ceramide through Caspase-3-Dependent Regulation of the “Sphingomyelin Cycle” in Fas-Induced Apoptosis , 2004, Cancer Research.
[31] J. Brouwers,et al. Identification of a family of animal sphingomyelin synthases , 2004, The EMBO journal.
[32] N. Ridgway,et al. The role of de novo ceramide synthesis in the mechanism of action of the tricyclic xanthate D609 Published, JLR Papers in Press, September 16, 2003. DOI 10.1194/jlr.M300300-JLR200 , 2004, Journal of Lipid Research.
[33] Y. Hannun,et al. BcR-induced Apoptosis Involves Differential Regulation of C16 and C24-Ceramide Formation and Sphingolipid-dependent Activation of the Proteasome* , 2003, The Journal of Biological Chemistry.
[34] A. Ganser,et al. Specific inhibition of bcr-abl gene expression by small interfering RNA. , 2003, Blood.
[35] T. Uchiyama,et al. Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] O. Linder,et al. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase – a report from the Swedish CML Group , 2002, British journal of haematology.
[37] H. Kantarjian,et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. , 2002, Blood.
[38] D. Marin,et al. The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. , 2002, Haematologica.
[39] L. Riboni,et al. Basic Fibroblast Growth Factor-induced Proliferation of Primary Astrocytes , 2001, The Journal of Biological Chemistry.
[40] J. Melo,et al. The molecular biology of chronic myeloid leukemia. , 2000, Blood.
[41] G. Müller,et al. Tumor Necrosis Factor Induces Ceramide Oscillations and Negatively Controls Sphingolipid Synthases by Caspases in Apoptotic Kym-1 Cells* , 1998, The Journal of Biological Chemistry.
[42] V. Maguer-Satta. CML and apoptosis: the ceramide pathway. , 1998, Hematology and cell therapy.
[43] Y. Hannun,et al. Sphingomyelin Synthase, a Potential Regulator of Intracellular Levels of Ceramide and Diacylglycerol during SV40 Transformation , 1998, The Journal of Biological Chemistry.
[44] D. Green,et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. , 1998, Blood.
[45] A. Gotoh,et al. Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase. , 1994, Leukemia.
[46] J. Osada,et al. Microsomal sphingomyelin accumulation in thioacetamide-injured regenerating rat liver: involvement of sphingomyelin synthase activity. , 1993, Carcinogenesis.
[47] Y. Hannun,et al. Programmed cell death induced by ceramide. , 1993, Science.
[48] D. Vance,et al. Stimulation of sphingomyelin biosynthesis by brefeldin A and sphingomyelin breakdown by okadaic acid treatment of rat hepatocytes. , 1992, The Journal of biological chemistry.
[49] E. Estey,et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] D. D. Jones,et al. An update of the enzymology and regulation of sphingomyelin metabolism. , 1990, Biochimica et biophysica acta.
[51] H. Kantarjian,et al. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high‐dose cytosine arabinoside , 1988, Cancer.
[52] K. Wirtz,et al. The synthesis of sphingomyelin in the Morris hepatomas 7777 and 5123D is restricted to the plasma membrane. , 1985, Biochimica et biophysica acta.
[53] E. P. Kennedy,et al. Cellular and enzymic synthesis of sphingomyelin. , 1982, Biochemistry.
[54] J. Kanfer,et al. The role of endogenous phosphatidylcholine and ceramide in the biosynthesis of sphingomyelin in mouse fibroblasts. , 1982, Biochimica et biophysica acta.
[55] J. Bernert,et al. Biosynthesis of sphingomyelin from erythro-ceramides and phosphatidylcholine by a microsomal cholinephosphotransferase. , 1981, Biochimica et biophysica acta.
[56] J. Kanfer,et al. The formation of sphingomyelin from phosphatidylcholine in plasma membrane preparations from mouse fibroblasts. , 1981, Biochimica et biophysica acta.
[57] Y Nishizuka,et al. Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. , 1980, The Journal of biological chemistry.
[58] Y. Nishizuka,et al. Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid-dependent protein kinase system. , 1979, Biochemical and biophysical research communications.
[59] N. Radin,et al. The enzymatic formation of sphingomyelin from ceramide and lecithin in mouse liver. , 1974, The Journal of biological chemistry.
[60] B. Ames,et al. The role of polyamines in the neutralization of bacteriophage deoxyribonucleic acid. , 1960, The Journal of biological chemistry.